Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:ARQTNYSE:CYHNASDAQ:OABI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.57+0.4%$4.40$7.96▼$24.15$12.96M0.6316,643 shs36,260 shsARQTArcutis Biotherapeutics$13.67+3.1%$13.85$7.86▼$17.75$1.63B1.762.25 million shs2.33 million shsCYHCommunity Health Systems$3.32+3.6%$3.30$2.24▼$6.29$464.41M2.122.39 million shs2.72 million shsOABIOmniAb$1.65-2.9%$1.60$1.22▼$4.96$201.52M-0.03666,317 shs404,428 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+0.39%-11.38%-20.92%-77.46%-84.95%ARQTArcutis Biotherapeutics0.00%+1.26%-5.79%-19.64%+67.73%CYHCommunity Health Systems0.00%+2.63%-20.88%+27.26%-4.74%OABIOmniAb0.00%-3.51%+7.14%-34.78%-60.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AARQTArcutis Biotherapeutics2.2967 of 5 stars3.41.00.00.03.31.70.6CYHCommunity Health Systems4.1596 of 5 stars3.03.00.04.52.72.50.6OABIOmniAb3.1535 of 5 stars3.51.00.00.03.23.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8037.53% UpsideCYHCommunity Health Systems 2.00Hold$4.1725.69% UpsideOABIOmniAb 3.00Buy$7.00324.24% UpsideCurrent Analyst Ratings BreakdownLatest CYH, ALVR, OABI, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025CYHCommunity Health SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight$2.00 ➝ $3.505/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/12/2025OABIOmniAbBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/25/2025CYHCommunity Health SystemsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$3.504/11/2025CYHCommunity Health SystemsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$4.00 ➝ $3.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/9/2025CYHCommunity Health SystemsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral4/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/27/2025OABIOmniAbRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$7.00 ➝ $4.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AARQTArcutis Biotherapeutics$196.54M8.29N/AN/A$1.35 per share10.13CYHCommunity Health Systems$12.63B0.04$2.53 per share1.31($12.06) per share-0.27OABIOmniAb$26.39M7.64N/AN/A$2.37 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)CYHCommunity Health Systems-$516M-$3.68N/A13.26N/A-3.85%N/A-0.87%7/23/2025 (Estimated)OABIOmniAb-$62.03M-$0.58N/AN/AN/A-229.11%-21.37%-18.84%8/6/2025 (Estimated)Latest CYH, ALVR, OABI, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025OABIOmniAb-$0.17-$0.17N/A-$0.17$4.49 million$4.15 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million4/23/2025Q1 2025CYHCommunity Health Systems-$0.10-$0.03+$0.07-$0.10$3.10 billion$3.16 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ACYHCommunity Health SystemsN/AN/AN/AN/AN/AOABIOmniAbN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78ARQTArcutis Biotherapeutics0.753.553.37CYHCommunity Health SystemsN/A1.441.30OABIOmniAbN/A4.704.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%ARQTArcutis BiotherapeuticsN/ACYHCommunity Health Systems84.99%OABIOmniAb72.08%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%ARQTArcutis Biotherapeutics9.40%CYHCommunity Health Systems11.70%OABIOmniAb8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableCYHCommunity Health Systems60,000140.31 million123.89 millionOptionableOABIOmniAb7122.14 million111.63 millionOptionableCYH, ALVR, OABI, and ARQT HeadlinesRecent News About These CompaniesOmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLCJune 17 at 5:56 AM | marketbeat.comOmniAb, Inc. (NASDAQ:OABI) Short Interest Down 15.8% in MayJune 3, 2025 | marketbeat.comChairman of OmniAb Picks Up 3.0% More StockMay 19, 2025 | uk.finance.yahoo.comOmniAb, Inc. (NASDAQ:OABI) Director Steven Love Purchases 25,000 SharesMay 15, 2025 | insidertrades.comInsider Buying: OmniAb, Inc. (NASDAQ:OABI) Director Buys 65,000 Shares of StockMay 14, 2025 | insidertrades.comOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston SummitMay 13, 2025 | businesswire.comIs OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comOmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comOmniAb, Inc. (OABI) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comOmniAb Introduces the xPloration® Partner Access ProgramMay 9, 2025 | tmcnet.comOmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comOmniAb Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | businesswire.comVERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid TumorsMay 5, 2025 | quiverquant.comVERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramMay 5, 2025 | globenewswire.comCompanies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In GrowthApril 25, 2025 | finance.yahoo.comOmniAb Announces Two New Appointments to its Board of DirectorsApril 21, 2025 | finance.yahoo.comOmniAb Appoints New Directors to BoardApril 21, 2025 | tipranks.comLeerink Partners Sticks to Their Buy Rating for OmniAb (OABI)April 20, 2025 | markets.businessinsider.comKurt A. Gustafson Sells 11,963 Shares of OmniAb, Inc. (NASDAQ:OABI) StockApril 2, 2025 | insidertrades.comAnalyst Forecasts Just Became More Bearish On OmniAb, Inc. (NASDAQ:OABI)March 29, 2025 | uk.finance.yahoo.comOmniAb price target lowered to $4 from $7 at RBC CapitalMarch 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYH, ALVR, OABI, and ARQT Company DescriptionsAlloVir NASDAQ:ALVR$2.57 +0.01 (+0.39%) As of 06/18/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Arcutis Biotherapeutics NASDAQ:ARQT$13.67 +0.41 (+3.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$13.66 -0.02 (-0.11%) As of 06/18/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Community Health Systems NYSE:CYH$3.32 +0.12 (+3.59%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$3.32 +0.00 (+0.15%) As of 06/18/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Community Health Systems, Inc. owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, and direct-to-consumer virtual health visits. The company was incorporated in 1996 and is headquartered in Franklin, Tennessee.OmniAb NASDAQ:OABI$1.65 -0.05 (-2.94%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.62 -0.03 (-2.06%) As of 06/18/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
